SCHEMBL2457734

SCHEMBL2457734

N[N+]12C=CN=CC1=C(Cc1ccccc1)N=C2c1cccc(OCc2ccccc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.41
MAOB P27338 4/20 0.40
MAOA P21397 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
PRKDC P78527 1/20 0.37
IGF1R P08069 2/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
DHFR P00374 1/20 0.36
BACE1 P56817 1/20 0.36
PDE4B Q07343 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
XBP1 P17861 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
DPYD Q12882 1/20 0.36
CYP4F2 P78329 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460398 0.87 MAOB (0.41) NR1H2MAOBMAOAPIK3CDPIK3CA
SCHEMBL2460371 0.87 NR1H2 (0.42) NR1H2MAOBMAOAMRGPRX4BACE1
SCHEMBL2464476 0.86 IGF1R (0.41) MAOBIGF1R
SCHEMBL3537072 0.86 MAOB (0.40) NR1H2MAOBPIK3CDPIK3CAPIK3CB
SCHEMBL2460471 0.86 IGF1R (0.42) MAOBIGF1R
SCHEMBL2458332 0.84 NR1H2 (0.39) NR1H2MAOBPIK3CDPIK3CAPIK3CB
SCHEMBL2457017 0.84 MAOB (0.39) NR1H2MAOBPIK3CDPIK3CAPIK3CB
SCHEMBL3538398 0.84 MAOB (0.38) NR1H2MAOBPIK3CDPIK3CAPIK3CB
SCHEMBL3535621 0.84 MAOB (0.38) NR1H2MAOBPIK3CDPIK3CAPIK3CB
SCHEMBL2460148 0.83 CFD (0.42) NR1H2MAOBPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 NR1H2 2603/4885MAOB 1546/4885MAOA 1799/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 NR1H2 2603/4885MAOB 1546/4885MAOA 1799/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 NR1H2 2603/4885MAOB 1546/4885MAOA 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.